Best Cell & Gene Therapy CDMOs in Europe

· updated as new inspection, certificate, and trial data enters the platform

Cell & Gene Therapy manufacturers on CDMO Signal: 43 listed with manufacturing sites in Europe. 8 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Novartis (in-house manufacturer, Signal Score 85.4), Takeda (also makes its own products, Signal Score 83.4) and Merck KGaA / MilliporeSigma (CDMO) (also makes its own products, Signal Score 81.9). Outside that set, higher Signal Scores on this list include FUJIFILM Diosynth Biotechnologies (Signal Score 86.7), Charles River Laboratories (Signal Score 86.3) and Minaris Advanced Therapies (Signal Score 83.1). A higher score there is not a fully evidenced record. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.

Cell & Gene Therapy CDMOs in Europe with the most regulatory evidence on file

Novartis
85.4
Basel, Switzerland
17 FDA inspections · 51 EMA/MHRA GMP certs
Last FDA inspection: 2026-06-24 · NAI
See the evidence →
FUJIFILM Diosynth Biotechnologies
86.7
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
0 FDA inspections · 35 EMA/MHRA GMP certs
Last FDA inspection: None on file
See the evidence →
AGC Biologics
79.9
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
4 FDA inspections · 27 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-29 · NAI
See the evidence →
Takeda
83.4
Boston, MA · Zurich, CH
4 FDA inspections · 20 EMA/MHRA GMP certs
Last FDA inspection: 2026-04-10 · NAI
See the evidence →
Charles River Laboratories
86.3
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
9 FDA inspections · 11 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-01 · NAI
See the evidence →
43
CDMOs tracked
42
Fully scored
14
With FDA records
70
FDA inspections
239
EMA/MHRA GMP certs

Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.

For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).

FDA inspection outcomes across these CDMOs: 33 NAI (no action), 37 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (52), United States (45), UNITED KINGDOM (45), Austria (39), Germany (28).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing all operator types.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
86.7 100.0 0 insp · 35 GMP None on file Expanding —
2
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
3
Basel, Switzerland
Fully evidenced
In-house manufacturer
85.4 97.4 17 insp · 51 GMP 2026-06-24 · NAI — 135 programs
4
TK
Boston, MA · Zurich, CH
Fully evidenced
Also makes its own products
83.4 100.0 4 insp · 20 GMP 2026-04-10 · NAI — 100 programs
5
MN
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
83.1 99.2 3 insp · 4 GMP 2025-11-25 · NAI Limited —
6
RP
Keele, UK · Sodertalje, SE
82.9 100.0 0 insp · 3 GMP None on file — —
7
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
81.9 98.8 2 insp · 2 GMP 2025-04-28 · VAI — 22 programs
8
SC
Prague, Czech Republic
81.6 100.0 0 insp · 5 GMP None on file — —
9
EF
Planegg, DE · San Diego, CA
81.6 100.0 7 insp · 0 GMP 2026-05-15 · NAI — —
10
CF
Les Ulis, FR
80.3 100.0 0 insp · 4 GMP None on file — —
11
BR
Glasgow, UK · Rockville, MD
Hiring · 16 open roles
Also makes its own products
80.3 97.2 6 insp · 10 GMP 2026-05-13 · VAI — —
12
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
13
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
79.5 100.0 — None on file Available —
14
BV
Turku, Finland
Hiring · 2 open roles
79.4 99.8 1 insp · 4 GMP 2024-12-19 · VAI — —
15
RC
Edinburgh, UK · Hopkinton, MA
Hiring · 8 open roles
79.3 96.8 1 insp · 1 GMP 2025-01-21 · VAI Available —
16
AA
Rockville, MD · Alachua, FL · Munich, DE
78.1 100.0 0 insp · 1 GMP None on file — —
17
NG
Leiden, NL
78.1 100.0 0 insp · 1 GMP None on file — —
18
ET
Jumet, BE
78.1 100.0 0 insp · 4 GMP None on file — —
19
PG
Berlin, DE
78.1 100.0 0 insp · 4 GMP None on file — —
20
CE
Basel, Switzerland
Hiring · 4 open roles
78.1 100.0 0 insp · 1 GMP None on file — —
21
XP
Bristol, United Kingdom
78.1 100.0 0 insp · 1 GMP None on file — —
22
AD
London, United Kingdom
78.1 100.0 0 insp · 2 GMP None on file — —
23
VG
San Sebastián, Spain
Hiring · 3 open roles
76.8 100.0 0 insp · 4 GMP None on file Available —
24
SY
Stirling, United Kingdom
76.8 100.0 1 insp · 8 GMP 2025-01-31 · NAI — —
25
CY
Toulouse, FR
76.8 100.0 0 insp · 2 GMP None on file — —
26
CN
Luxembourg, LU
76.8 100.0 0 insp · 1 GMP None on file — —
27
HH
London, United Kingdom
76.8 100.0 0 insp · 4 GMP None on file — —
28
OX
Oxford, United Kingdom
Hiring · 4 open roles
Fully evidenced
Also makes its own products
76.2 100.0 2 insp · 13 GMP 2024-06-17 · NAI Available 7 programs
29
MB
Bergisch Gladbach, Germany
Fully evidenced
73.0 100.0 0 insp · 2 GMP None on file — 8 programs
30
Basel, Switzerland
Hiring · 100+ open roles
Fully evidenced
72.8 86.6 11 insp · 8 GMP 2025-09-29 · VAI — 1 program
31
RT
Rome, IT
Fully evidenced
71.1 100.0 0 insp · 4 GMP None on file — 1 program
32
CG
Marlborough, MA · Uppsala, SE
Platform provider
65.5 — — None on file — —
33
VE
Rockville, MD · Memphis, TN · Keele, United Kingdom
64.0 — — None on file — —
34
RA
Stockholm, Sweden
63.0 — — None on file — —
35
AB
Research Triangle, NC · San Sebastian, ES
Also makes its own products
61.8 — — None on file — 10 programs
36
OR
London, United Kingdom
Platform provider
59.0 — — None on file — —
37
CP
Stevenage, United Kingdom
Academic / national centre
59.0 — — None on file — —
38
EX
La Rochelle, France
Hiring · 3 open roles
59.0 — — None on file — —
39
CZ
Cologne, Germany
59.0 — — None on file — —
40
AM
Gerenzano, Italy
59.0 — — None on file — —
41
CV
Cologne, Germany
56.5 — — None on file — —
42
CX
Freiburg, DE
Reagent supplier
56.5 — — None on file — —
—
Germany
Profiled — 2 insp · 2 GMP 2023-09-08 · VAI — —
How we score CDMOs →

What to evaluate in a Cell & Gene Therapy CDMO

Integrated vs point-solution CDMO
Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.
Regulatory record by process class
Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.
Chain-of-identity + cold chain
Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.
Commercial track record
For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.

EMA and MHRA regulatory considerations for European-manufactured programs

European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.

QP release requirements and how they affect CDMO selection

Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.

Which European CDMOs also cover FDA (US) regulatory geography?

European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.

Cell & Gene Therapy CDMOs — Frequently Asked Questions

Who are the top Cell & Gene Therapy CDMOs?
Among Cell & Gene Therapy manufacturers with a fully evidenced Signal Score (all four pillars and at least one ClinicalTrials.gov match), the highest are Novartis, Takeda, Merck KGaA / MilliporeSigma (CDMO). The table above is the full list. CDMOs cannot pay to change a score.
How many Cell & Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 14 Cell & Gene Therapy CDMOs with FDA inspection records and 239 EMA/MHRA GMP certificates across the group.
What should I look for in a cell and gene therapy CDMO?
Start with process class match — cell therapy vs vector vs both. For ex vivo programs benefit from integrated CDMOs. Verify inspection record on the specific process class, confirm capacity match to your patient volume, and prioritize CDMOs with commercial-scale posture for late-stage work.
How many cell and gene therapy CDMOs does CDMO Signal track?
The table on this page is the live list: the union of cell therapy, AAV, lentiviral, adenoviral, and gene-therapy-tagged manufacturers. This is the broadest advanced-therapy candidate list on the platform. CDMOs cannot pay to change a score.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this Cell & Gene Therapy shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
Cell Therapy CDMOs AAV / Gene Therapy CDMOs Lentiviral Vector CDMOs Gene Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Viral Vector

Best cell and gene therapy CDMO in Europe

Cell therapy and gene therapy manufacturers with European facilities, ranked together.